Previously Senior Vice President and Managing Director European
Operations, Mancuso now oversees Patheon's global commercial
TORONTO, Jan. 25, 2012 /CNW/ - Patheon (TSX: PTI) a global provider of
drug development and manufacturing services to the international
pharmaceutical industry announced today that Antonella Mancuso has been
promoted to President, Global Commercial Operations and Chief
Manufacturing Officer, responsible for Patheon's global commercial
manufacturing operations . Ms. Mancuso will assume responsibility for
all of Patheon's commercial operating units in North America and
Europe. In her previous role as Senior Vice President and Managing
Director European Operations, Ms. Mancuso managed the company's
commercial manufacturing operations outside of North America.
"Antonella's demonstrated success focusing on the customer, on quality,
and on margins is in direct alignment with our company strategy and
directly supports the needs of our customers, our employees and our
shareholders. I am excited about this opportunity to unify our
manufacturing services business and leverage best practices across our
business," stated Jim Mullen, Patheon's Chief Executive Officer.
Ms. Mancuso joined Patheon in 2001 as Production Manager of Patheon's
facility in Monza, Italy, becoming Site Director in June 2002. She has
held other positions with increasing responsibility culminating with
her appointment to her new position as President, Global Commercial
Operations and Chief Manufacturing Officer. Prior to joining Patheon,
Ms. Mancuso held progressively senior roles in production and
manufacturing during her six years at Bristol-Myers Squibb in Italy.
Antonella has also worked at Select Pharma and Bioprogress. She holds a
degree in Pharmaceutical Chemistry and Technology from La Sapienza
University of Rome.
Patheon Inc. (TSX: PTI) is a leading global provider of contract
development and manufacturing services to the global pharmaceutical
industry. The company provides the highest quality products and
services to approximately 300 of the world's leading pharmaceutical and
biotechnology companies. Its services range from preclinical
development through commercial manufacturing of a full array of dosage
forms including parenteral, soft gel, solid and liquid forms.
The company's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization.
The company's integrated development and manufacturing network of 10
manufacturing facilities, nine development centers and one clinical
trial material packaging facility across North America and Europe,
enables customer products to be launched with confidence anywhere in
SOURCE Patheon Inc.
For further information:
Investor Relations and Corporate Communications
Tel: (919) 226-3313